Medicus Pharma CEO details Teverelix progress – ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study for Teverelix, reporting that the revised protocol had received Institutional Review Board approval and had been accepted by the US Food and Drug Administration subject to operational observations. CEO Raza Bokhari told Proactive that the company had acquired the Teverelix development programme through its purchase of UK-based Antev. He described Teverelix® as a next-generation hormone antagonist being developed for two men’s health indications. We have had a good day at Medicus Pharma (NASDAQ:MDCX). For the benefit of your viewers, towards the end of last summer, we added a second asset to our portfolio through the acquisition of a UK-based company called Antev. Through that acquisition, we took over the clinical development programme for Teverelix, a next-generation hormone antagonist. We are pursuing two indications in men’s health: one involving patients with advanced prostate cancer and a high cardiovascular risk profile, and another involving a novel study designed to prevent the relapse of acute urinary retention, primarily due to an enlarged prostate. The second study inherited from Antev wa...